Natasja Bruin De

I serve as the Project Manager R&D at benfovir AG, a clinical-stage pharmaceutical company pioneering innovative treatments for viral diseases and cancers. At benfovir AG, we're dedicated to a cutting-edge approach that disrupts sugar and lipid metabolism in infected or cancerous cells, hindering the formation of essential building blocks necessary for virus production and cell proliferation. This mechanism of action presents numerous exciting challenges.

In my role, I oversee the design, planning, implementation, and evaluation of benfovir's non-clinical research projects. My responsibilities include providing scientific input, managing project progress and timelines, nurturing relationships with service providers, and ensuring thorough documentation completion.

I'm excited being part of this dynamic and innovative team and eagerly anticipate contributing to the advancement of benfovir's therapeutic approach.

Find out more at: https://benfovir.com/ and https://oxy5.com/

Since 2022, I have served as the Medical Information Manager at Innoplexus AG, located in Eschborn, Germany. Prior to this role, from 2012 to 2022, I held the position of pharmacology group leader at the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) within the Preclinical Research Department in Frankfurt/Main, Germany.

Before my tenure at Fraunhofer, I accumulated over a decade of experience as a neuroscientist and pharmacologist in both pharmaceutical and nutraceutical industries. Specifically, from 2005 to 2011, I served as principal scientist and study director at Solvay Pharmaceuticals/Abbott Healthcare Products in Weesp, The Netherlands. In this capacity, I spearheaded pharmacology efforts across various R&D projects.

My journey in the field began with two postdoctoral positions focusing on CNS/Neuroscience indications. From 2001 to 2005, I pursued these roles at Johnson & Johnson PRD/Janssen Pharmaceutica N.V. in Beerse, Belgium, and at Numico N.V. (now Danone Nutricia Research) in Wageningen, The Netherlands.

Throughout my career, I have authored over 50 peer-reviewed publications, reflecting my expertise in drug development within the pharmaceutical industry. My specialization lies in pharmacology and target validation, with a focus on neuroscience indications and inflammatory and autoimmune diseases, including Alzheimer’s disease, multiple sclerosis, schizophrenia, epilepsy, pain, arthritis, psoriasis, and dermatitis.